<DOC>
	<DOCNO>NCT01999803</DOCNO>
	<brief_summary>This phase I , multicentre randomise , double-blind , placebo-controlled trial ass safety tolerability continuous i.c.v . administration sNN0029 infusion solution dose 4Âµg/day patient Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>A Safety Study sNN0029 Administration Via Intracerebroventricular Route Patients With ALS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Clinical diagnosis ALS classify definite , probable without additional laboratory evidence , accord revise World Federation Neurology ( WFN ) El Escorial criterion . If patient treat riluzole , must stable dose least past 30 day prior screen . The patient , opinion investigator , medically fit undergo surgery require stereotactic implantation catheter infusion pump . 1 . Impaired respiratory function judge pose risk patient anaesthesia device implantation . 2 . Hypertension define blood pressure &gt; 160 mmHg systolic &gt; 90 mmHg diastolic . 3 . Values coagulation parameter include platelet count , normalised prothrombin complex ( PKINR ) , activate partial thromboplastin time ( APTT ) outside normal range . 4 . Ophthalmological examination ( fundus photography , visual acuity perimetry ) clinically significant finding imply safety concern study . 5 . Diagnosis diabetes mellitus . 6 . History structural brain disease ALS , include tumour hyperplasia . 7 . An MRI brain cervical spine , Magnetic Resonance Angiography ( MRA ) brain finding tumours potential source pathological bleeding , abnormality may interfere assessment safety efficacy would , judgment investigator , represent surgical risk patient . If MRI and/or MRA perform within 1 month prior screen , result examination use . 8 . Any disorder precludes surgical procedure ( e.g. , sign sepsis inadequately treated infection ) , alters wind heal ( e.g. , include bleed disorder ) , render chronic i.c.v . delivery device implant medically unsuitable . 9 . Presence risk increase uncontrolled bleeding and/or risk bleed manage optimally due : i. anatomical factor near implant site ( e.g. , vascular abnormality , neoplasm , abnormality ) , ii . underlie disorder coagulation cascade , platelet function , platelet count ( e.g. , haemophilia , Von Willebrand 's disease , liver disease , medical condition ) iii . administration antiplatelet anticoagulant medication preoperative period 10 . A personal history thromboembolic disease . A family history thromboembolic disease prompt laboratory assessment exclude hereditary liability patient declare eligible . 11 . Presence additional risk factor thromboembolism obesity ( BMI &gt; 35 ) use oestrogens include combine contraceptive pill . 12 . Presence implant shunt drainage CSF implanted Central Nervous System ( CNS ) catheter . 13 . Clinically significant abnormality haematology clinical chemistry parameter assess investigator . 14 . Serological evidence Hepatitis B virus ( HBV ) , Hepatitis C virus ( HCV ) Human immunodeficiency virus ( HIV ) 15 . Ongoing medical condition accord investigator would interfere conduct assessment study . Examples medical disability ( e.g. , severe degenerative arthritis , compromise nutritional state , peripheral neuropathy ) would interfere assessment safety efficacy investigational product device performance , would compromise ability patient undergo study procedure ( e.g. , MRI ) , give inform consent . 16 . Participation another clinical trial investigational drug device within 3 month prior screen visit . 17 . For woman : pregnant , breast feeding and/or fecund woman unwillingness use adequate contraception trial : Established use oral , injected implant hormonal method contraception NOT contain oestrogen . Placement intrauterine device . Barrier method contraception : Condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>